[Special Stock] Peptron Rallies for Fourth Day on "Lupone" Approval, Touches 2.6 Million KRW

< p >Peptron continued its upward trend for the fourth consecutive day, surpassing 2.6 million KRW during intraday trading.< /p >
< p >As of 9:16 a.m. on July 17, Peptron was trading at 2,585,000 KRW on the Korea Exchange, up 215,000 KRW (9.07%) from the previous day. The stock reached an all-time high of 2,615,000 KRW during the session.< /p >
< p >News of the approval of "Lupone," a treatment for prostate cancer and precocious puberty, drove up the share price. On July 15, Peptron announced that it had received product approval from the Ministry of Food and Drug Safety for Lupone, a one-month sustained-release treatment for prostate cancer and precocious puberty. Lupone is the first drug developed using Peptron's long-acting drug delivery platform. Um Minyong, a researcher at Shinhan Investment Corp., stated, "Lupone is a product for which Takeda's once-monthly Lupron is the original. Among major pharmaceutical companies such as AstraZeneca, Sanofi, and Ipsen, only a very few have received approval. In Korea, Peptron is the only company to have met the criteria for bioequivalence and received approval solely based on its own technology, manufacturing, and clinical capabilities. This achievement deserves attention."< /p >